Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-29

Engineering of the porcine genome for xenotransplantation studies in primates: a step towards clinical application

Objective

The ultimate goal of our Consortium is to generate the necessary data to allow xenotransplantation to progress towards its initial clinical phase. The data generated during this project will encompass both efficacy and safety aspects of xeno-transplantation. Tools that will be used to reach this ambitious objective encompass state-of-the-art biomolecular technologies and in vivo models. XENOME aims to produce a "super-engineered" pig, i.e. a pig with a newly generated genotype that will improve the efficacy and safety profile of xenotransplantation. Assessments of efficacy will first take advantage of existing pig lines expressing human complement regulators, thrombomodulin (TM) and knock-out for a-Gal transferase. Using the most suitable background, further engineering will eliminate one or more PERV sequences. Additional transgenes, such as HO-1, CD39 and other molecules able to control immune responses, endothelial cell activation and subsequent microangiopathy, will be added.

The ultimate pig strain will thus combine the already available background with novel molecules exhibiting anti-inflammatory, anticoagulant and immunosuppressive properties. In addition, an effective immuno-suppression regimen will be defined and new pharmaceutical agents will be tested. A strong safety framework will also be established that may allow, at some stage, progression of xenotransplantation into the clinic. This will involve development of technologies enabling the timely diagnosis of infection, design of a safety plan for an efficacious containment of an untoward infectious event, breeding of a herd of "clean" source pigs, inactivation of PERV sequences and provide safety-related data deriving from long-term in vivo studies in primate xenograft recipients. Finally, the project will also provide a strong ethical, social (especially regarding public communication) and regulatory framework for xenotransplantation research (and possibly clinical application).

Fields of science

Programme(s)

Topic(s)

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

IP - Integrated Project

Coordinator

AZIENDA OSPEDALIERA DI PADOVA
EU contribution
No data
Address
Via Giustiniani 2
PADOVA
Italy

See on map
Links
Total cost
No data

Participants (25)

Share this page

Download

Last update: 2 May 2012

My Booklet

Permalink: https://cordis.europa.eu/project/id/37377

European Union, 2024